三个监管机构对新型疗法的审查。 - Suppr

Suppr

超能文献

Review of novel therapeutics by three regulatory agencies.

作者信息

Marijon Eloi, Le Heuzey Jean-Yves, Fauchier Laurent

出版信息

N Engl J Med. 2012 Sep 20;367(12):1166; author reply 1166-7. doi: 10.1056/NEJMc1208803.

DOI:10.1056/NEJMc1208803

PMID:22992091

Abstract

摘要

相似文献

Review of novel therapeutics by three regulatory agencies.

N Engl J Med. 2012 Sep 20;367(12):1166; author reply 1166-7. doi: 10.1056/NEJMc1208803.

Review of novel therapeutics by three regulatory agencies.

N Engl J Med. 2012 Sep 20;367(12):1165-6; author reply 1166-7. doi: 10.1056/NEJMc1208803.

Regulatory review of novel therapeutics--comparison of three regulatory agencies.

N Engl J Med. 2012 Jun 14;366(24):2284-93. doi: 10.1056/NEJMsa1200223. Epub 2012 May 16.

A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.

N Engl J Med. 2017 Apr 20;376(16):1499-1501. doi: 10.1056/NEJMp1700202. Epub 2017 Mar 1.

Paying for drug approvals--who's using whom?

N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.

An ethical dilemma. Patents & profits v. access & affordability.

J Leg Med. 2012 Jan;33(1):115-28. doi: 10.1080/01947648.2012.657939.

What ails the FDA?

N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.

Muddied messages about FDA.

Nat Biotechnol. 2003 Jul;21(7):732-3. doi: 10.1038/nbt0703-732.

FDA and EMEA pool scientific advice.

Nat Biotechnol. 2004 Dec;22(12):1490-1. doi: 10.1038/nbt1204-1490.

FDA performance goals for approving drugs and biologics.

JAMA. 2009 Jul 8;302(2):189-91. doi: 10.1001/jama.2009.974.

引用本文的文献

A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.

Br J Clin Pharmacol. 2013 Sep;76(3):396-411. doi: 10.1111/bcp.12085.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Review of novel therapeutics by three regulatory agencies.

N Engl J Med. 2012 Sep 20;367(12):1166; author reply 1166-7. doi: 10.1056/NEJMc1208803.

Review of novel therapeutics by three regulatory agencies.

N Engl J Med. 2012 Sep 20;367(12):1165-6; author reply 1166-7. doi: 10.1056/NEJMc1208803.

Regulatory review of novel therapeutics--comparison of three regulatory agencies.

N Engl J Med. 2012 Jun 14;366(24):2284-93. doi: 10.1056/NEJMsa1200223. Epub 2012 May 16.

A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.

N Engl J Med. 2017 Apr 20;376(16):1499-1501. doi: 10.1056/NEJMp1700202. Epub 2017 Mar 1.

Paying for drug approvals--who's using whom?

N Engl J Med. 2007 Apr 26;356(17):1697-700. doi: 10.1056/NEJMp078041. Epub 2007 Apr 13.

An ethical dilemma. Patents & profits v. access & affordability.

J Leg Med. 2012 Jan;33(1):115-28. doi: 10.1080/01947648.2012.657939.

What ails the FDA?

N Engl J Med. 2005 Mar 17;352(11):1063-6. doi: 10.1056/NEJMp058003.

Muddied messages about FDA.

Nat Biotechnol. 2003 Jul;21(7):732-3. doi: 10.1038/nbt0703-732.

FDA and EMEA pool scientific advice.

Nat Biotechnol. 2004 Dec;22(12):1490-1. doi: 10.1038/nbt1204-1490.

FDA performance goals for approving drugs and biologics.

JAMA. 2009 Jul 8;302(2):189-91. doi: 10.1001/jama.2009.974.

引用本文的文献

A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.

Br J Clin Pharmacol. 2013 Sep;76(3):396-411. doi: 10.1111/bcp.12085.